Cytomed Therapeutics

CytoMed Therapeutics develops off-the-shelf cellular immunotherapies using gamma delta T cells and natural killer cells, including iPSC-derived gdNKT and CAR-γδ T cell platforms, for solid and haematological cancers. The company translates patent-pending technologies into therapeutics for customers and organisations, and offers iPSC generation and differentiation into cellular products, supported by GMP facilities enabling deployment across regional markets.

Cytomed Therapeutics is public listed, with a valuation of -.

Alternatives.pe lists Cytomed Therapeutics's financials, valuation trends, ownership structure and transaction activity.

You're on a preview of a profileGet a free trial to view it in full

Last Updated: 2026-07-21

You're on a preview of a profileGet a free trial to view it in full

Last Updated: 2026-07-21

Loading, please wait...

All information here may not be reproduced without explicit written permission from Alternatives.pe.

Glossary

Cytomed Therapeutics

Cytomed Therapeutics

Key Team Members

Documents

Related News

Key Team Members